[go: up one dir, main page]

WO2000073415A3 - Method de transfert d'antigenes dans des cellules dendritiques - Google Patents

Method de transfert d'antigenes dans des cellules dendritiques Download PDF

Info

Publication number
WO2000073415A3
WO2000073415A3 PCT/EP2000/004712 EP0004712W WO0073415A3 WO 2000073415 A3 WO2000073415 A3 WO 2000073415A3 EP 0004712 W EP0004712 W EP 0004712W WO 0073415 A3 WO0073415 A3 WO 0073415A3
Authority
WO
WIPO (PCT)
Prior art keywords
transfer
dendritic cells
antigens
cells
cocultivation
Prior art date
Application number
PCT/EP2000/004712
Other languages
English (en)
Other versions
WO2000073415A2 (fr
Inventor
Catia Traversari
Vincenzo Russo
Claudio Bordignon
Original Assignee
Genera Spa
Catia Traversari
Vincenzo Russo
Claudio Bordignon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera Spa, Catia Traversari, Vincenzo Russo, Claudio Bordignon filed Critical Genera Spa
Priority to IL14677700A priority Critical patent/IL146777A0/xx
Priority to JP2001500731A priority patent/JP2003501019A/ja
Priority to CA002375349A priority patent/CA2375349A1/fr
Priority to HK02108610.1A priority patent/HK1047131A1/zh
Priority to EP00936788A priority patent/EP1185626A2/fr
Priority to KR1020017015173A priority patent/KR20020013563A/ko
Priority to AU52159/00A priority patent/AU772703B2/en
Publication of WO2000073415A2 publication Critical patent/WO2000073415A2/fr
Publication of WO2000073415A3 publication Critical patent/WO2000073415A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4277—Fusion proteins originating from gene translocation in cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode de transfert d'antigènes dans des cellules dendritiques, comprenant la coculture de cellules denditriques avec des cellules transfectées avec, ou exprimant, les antigènes désirés.
PCT/EP2000/004712 1999-05-28 2000-05-24 Method de transfert d'antigenes dans des cellules dendritiques WO2000073415A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL14677700A IL146777A0 (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells
JP2001500731A JP2003501019A (ja) 1999-05-28 2000-05-24 抗原の樹状細胞への移入方法
CA002375349A CA2375349A1 (fr) 1999-05-28 2000-05-24 Method de transfert d'antigenes dans des cellules dendritiques
HK02108610.1A HK1047131A1 (zh) 1999-05-28 2000-05-24 一種將抗原轉移到樹突狀細胞的方法
EP00936788A EP1185626A2 (fr) 1999-05-28 2000-05-24 Method de transfert d'antigenes dans des cellules dendritiques
KR1020017015173A KR20020013563A (ko) 1999-05-28 2000-05-24 수상세포로 항원을 전달하는 방법
AU52159/00A AU772703B2 (en) 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001180A IT1312570B1 (it) 1999-05-28 1999-05-28 Metodo per il traferimento di antigeni a cellule dendritiche.
ITMI99A001180 1999-05-28

Publications (2)

Publication Number Publication Date
WO2000073415A2 WO2000073415A2 (fr) 2000-12-07
WO2000073415A3 true WO2000073415A3 (fr) 2001-03-01

Family

ID=11383060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004712 WO2000073415A2 (fr) 1999-05-28 2000-05-24 Method de transfert d'antigenes dans des cellules dendritiques

Country Status (10)

Country Link
EP (1) EP1185626A2 (fr)
JP (1) JP2003501019A (fr)
KR (1) KR20020013563A (fr)
CN (1) CN1187442C (fr)
AU (1) AU772703B2 (fr)
CA (1) CA2375349A1 (fr)
HK (1) HK1047131A1 (fr)
IL (1) IL146777A0 (fr)
IT (1) IT1312570B1 (fr)
WO (1) WO2000073415A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506596B2 (en) 2000-06-01 2003-01-14 Anna-Lena Spetz-Holmgren Method of DNA transfer
CN100392074C (zh) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
CA2602434C (fr) * 2005-04-08 2016-06-07 Argos Therapeutics, Inc. Compositions a base de cellules dendritiques et methodes associees

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006723A1 (fr) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Procede de marquage de cellules eucariotes par utilisation d'un recepteur de surface cellulaire en tant que marqueur
WO1995034638A1 (fr) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
EP0904786A1 (fr) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Vaccination contre les tumeurs avec l'utilisation des cellules autologues transduits avec un antigène
WO1999042564A2 (fr) * 1998-02-20 1999-08-26 The Rockefeller University Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006723A1 (fr) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Procede de marquage de cellules eucariotes par utilisation d'un recepteur de surface cellulaire en tant que marqueur
WO1995034638A1 (fr) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
EP0904786A1 (fr) * 1997-08-22 1999-03-31 Science Park Raf S.p.A. Vaccination contre les tumeurs avec l'utilisation des cellules autologues transduits avec un antigène
WO1999042564A2 (fr) * 1998-02-20 1999-08-26 The Rockefeller University Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBERT ET AL: "Resurrecting the dead: DCs cross-present antigen derived from apoptotic cells on MHC I", IMMUNOLOGIST,CA,HOGREFE AND HUBER PUBLISHERS, TORONTO, vol. 6, no. 5, September 1998 (1998-09-01), pages 194 - 198, XP002119454, ISSN: 1192-5612 *
ALBERT MATTHEW L ET AL: "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.", NATURE (LONDON), vol. 392, no. 6671, 5 March 1998 (1998-03-05), pages 86 - 89, XP002154749, ISSN: 0028-0836 *
RUSSO V ET AL: "Acquisition of intact allogeneic HLA molecules by human dendritic cells.", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), Forty-first Annual Meeting of the American Society of Hematology;New Orleans, Louisiana, USA; December 3-7, 1999, pages 678a, XP002154751, ISSN: 0006-4971 *
RUSSO V ET AL: "Cocultivation of non-diving dendritic cells with a retroviral vector-producing cell line allows transfer of the relevant antigens by a vector-independent mechanism.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 667A, XP000971149, ISSN: 0006-4971 *
RUSSO VINCENZO ET AL: "Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 5, 29 February 2000 (2000-02-29), Feb. 29, 2000, pages 2185 - 2190, XP002154750, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
ITMI991180A1 (it) 2000-11-28
EP1185626A2 (fr) 2002-03-13
HK1047131A1 (zh) 2003-02-07
IL146777A0 (en) 2002-07-25
CA2375349A1 (fr) 2000-12-07
AU772703B2 (en) 2004-05-06
IT1312570B1 (it) 2002-04-22
AU5215900A (en) 2000-12-18
KR20020013563A (ko) 2002-02-20
CN1360628A (zh) 2002-07-24
CN1187442C (zh) 2005-02-02
WO2000073415A2 (fr) 2000-12-07
JP2003501019A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
AU2001238677A1 (en) Method for preparing anti-mif antibodies
AU1292700A (en) Immune cells having predefined biological specificity, comprising chimeric t cell receptor
WO1999036511A3 (fr) Vecteurs de therapie genique du virus de l'immunodeficience feline
AU3198200A (en) Prrsv vaccines
MXPA01013450A (es) Transferencia citoplasmica para celulas receptoras de-diferenciacion.
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
AU7445900A (en) Novel hemopoietin receptor protein, nr12
AU4935000A (en) Antibodies
AU2002230470A1 (en) Process for preparing pouches
AUPQ485999A0 (en) P. gingivalis antigenic composition
AU2001258447A1 (en) Method for transmitting messages
EP1156042A4 (fr) Procede de preparation de carbonate de glycerol
WO2001040242A3 (fr) Forme cristalline iii de la 6-o-methylerythromycine a
AU2001294577A1 (en) Methods for preparing interferon producing dentitric cells
ZA200007458B (en) Method of preparing a fuel cell.
AU5537300A (en) Method for controlling the transmission power
AU5577800A (en) Method for producing cloned cows
AU2101600A (en) Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
IL148266A0 (en) Apo-2 receptor antibodies
AU1097301A (en) Humanization of non-human, mammalian antibodies
AU2002215980A1 (en) Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferationinhibitors
AU2855501A (en) Method for obtaining a powder containing viable microorganisms, powder obtained according to this method and device for carrying out said method
AU6726598A (en) Method for generating embryogenic cell cultures for the production of transgenicbananas (musa spp.)
WO2000073415A3 (fr) Method de transfert d'antigenes dans des cellules dendritiques
AU5585700A (en) Process for making 2,4,6, 8,10,12- hexanitro- 2,4,6,8,10, 12- hexa azatetracyclo(5.5.0. 05,9.03,11} -dodecane

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808155.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000936788

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 500731

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2375349

Country of ref document: CA

Ref document number: 2375349

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017015173

Country of ref document: KR

Ref document number: 52159/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09979308

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020017015173

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000936788

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 52159/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000936788

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017015173

Country of ref document: KR